Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/4521
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSehrawat, Sharvan-
dc.date.accessioned2023-08-11T10:37:57Z-
dc.date.available2023-08-11T10:37:57Z-
dc.date.issued2022-
dc.identifier.citationhttps://doi.org/10.1016/j.jbc.2022.102596en_US
dc.identifier.uriJournal of Biological Chemistry, 298(12), 102596.-
dc.identifier.urihttp://hdl.handle.net/123456789/4521-
dc.descriptionOnly IISER Mohali authors are available in the record.en_US
dc.description.abstractNovel vaccination strategies are crucial to efficiently control tuberculosis, as proposed by the World Health Organization under its flagship program “End TB Strategy.” However, the emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), particularly in those coinfected with HIV-AIDS, constitutes a major impediment to achieving this goal. We report here a novel vaccination strategy that involves synthesizing a formulation of an immunodominant peptide derived from the Acr1 protein of Mtb. This nanoformulation in addition displayed on the surface a toll-like receptor-2 ligand to offer to target dendritic cells (DCs). Our results showed an efficient uptake of such a concoction by DCs in a predominantly toll-like receptor-2–dependent pathway. These DCs produced elevated levels of nitric oxide, proinflammatory cytokines interleukin-6, interleukin-12, and tumor necrosis factor-α, and upregulated the surface expression of major histocompatibility complex class II molecules as well as costimulatory molecules such as CD80 and CD86. Animals injected with such a vaccine mounted a significantly higher response of effector and memory Th1 cells and Th17 cells. Furthermore, we noticed a reduction in the bacterial load in the lungs of animals challenged with aerosolized live Mtb. Therefore, our findings indicated that the described vaccine triggered protective anti-Mtb immunity to control the tuberculosis infection.en_US
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.subjectMycobacterium tuberculosis epitopeen_US
dc.subjectTargeting dendritic cells with TLR-2en_US
dc.subjectligand–coated nanoparticles loadeden_US
dc.titleTargeting dendritic cells with TLR-2 ligand–coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunityen_US
dc.typeArticleen_US
Appears in Collections:Research Articles

Files in This Item:
File Description SizeFormat 
Need To Add…Full Text_PDF..pdf15.36 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.